KoolavAll agenciesBy industryBy disciplineReportsHow we vet
All agencies · Brand Naming

Brand Institute review

CONDITIONAL for Brand Naming

Worth a conversation about Brand Naming once the caveats below are settled.

A 1993-founded pharmaceutical naming specialist with an unusually deep regulatory layer - ex-FDA/EMA officials, POCA name-safety screening and published 2025 approval rates by jurisdiction - but it publishes no fees, no timelines and no shortlist size.

Pricing: several published tiers Reported — not published by the agency
Clutch profile shows 5.0 out of 5 from 3 verified reviews, cost rated 4.8, and a stated minimum project size of $5,000+, with most reviewed projects in the $50,000-$199,999 band. source ↗

Score 3.2/5Confidence: lowLast evaluated 2026-08-26Website

How it scored

Every dimension is scored against this discipline’s published rubric. Open one to see the claim it was scored on, what the rubric measures there and how much it weighs, and where the evidence came from.

Named work in marketStrong

The about page attributes a long list of real, in-market pharmaceutical brands to the firm - Victoza, Saxenda, Kyleena, Comirnaty, Fasenra, Fetroja, Nyxoid, Restasis, Nucala, REZDIFFRA, EPKINLY, UBRELVY, XCOPRI - and names clients including Pfizer, Roche, Amgen, AstraZeneca, GSK, Sandoz, Shionogi, Mundipharma and Celltrion. The press release archive carries dated, client-joint announcements (Arvinas / bavdegalutamide, Dec 5 2022; Bavarian Nordic / JYNNEOS, Nov 28 2022; TADLIQ, FUROSCIX, VEGZELMA, APONVIE) and is current, with the most recent release dated Apr 17 2026. The portfolio is not decades-old glory: 2025 jurisdiction-level approval rates and 2026 releases show a working current practice. Held off Excellent because the specific name credits rest largely on the firm's own press releases - the Wikipedia entry on the company carries an explicit maintenance warning that it may rely excessively on sources too closely associated with the subject, and a FiercePharma piece on the Comirnaty naming returned 403 so it could not be read first-hand. Three verified Clutch reviews independently confirm the healthcare regulatory-naming practice is real, but not individual credits.

What this dimension measures: Names the firm created that are verifiably in use by real companies — the strongest evidence this category can offer, because a shipped name is public. Attributed, checkable names for recognisable clients score 4-5. Case studies without the client's confirmation, or a portfolio dominated by decades-old wins, score 2-3: naming credits are notoriously contested and old glory says little about the current team. No attributable names scores 2. Counts for 25% of the weighted score.

Evidence: partly checkable — corroborated in part against the sources below; the remainder rests on the agency’s own account.

Methodology and linguistic screeningStrong

Unusually specific for this category, and named at the step level rather than described in the abstract. Screening runs across a stated 268 international trademark databases using BrandReality (a pharma-in-use legal prescreen) and a Common-Law Prescreen; name safety is checked against the FDA POCA system with a stated pass condition that candidates not exceed a 75 percent combined phonetic and orthographic score. Linguistic evaluation is performed by in-country native-speaking professionals in the client's primary markets, which is the multi-market check this dimension asks for. Name recommendations are tiered by regulatory viability and research results are benchmarked to historical norms. The medical device page describes a three-stage sequence: consultation, creative development plus regulatory screening, then linguistic validation and market testing. The regulatory layer is a genuine differentiator - the Drug Safety Institute subsidiary (established 2004) is staffed by former FDA, EMA, Health Canada, AMA and WHO naming officials and publishes 2025 approval rates by jurisdiction (FDA 88 percent, EMA 76 percent, Health Canada 97 percent, Japan 76 percent, USAN 76 percent, INN 79 percent). Short of Excellent because how naming territories are developed and how many candidates are generated are never described, and every step above is self-published.

What this dimension measures: A published, specific process: how territories are developed, how many candidates are generated, and — critically — linguistic and cultural screening across the markets the client sells in. A described multi-market linguistic check with named steps scores 4-5. A generic 'we brainstorm then check' description scores 2-3. No described method scores 2. Weight specificity: the firms that do this well tend to write about it in detail, so vagueness is informative. Counts for 20% of the weighted score.

Evidence: vendor stated — the agency’s own claim, recorded as theirs rather than ours.

Trademark screening rigorAdequate

A pre-screening step is clearly stated and staffed: trademark searches are run by an in-house team of attorneys and paralegals, using the BrandReality pharma-in-use legal prescreen and a common-law prescreen across 268 databases, with stated report customization. That is well above silence. It does not reach the top band because the firm never states the boundary the rubric rewards - nowhere on the pages read does it say that its screening is a prescreen rather than legal clearance, nor does it describe a handoff to the client's trademark counsel or any class strategy. Employing attorneys in-house makes that silence more consequential, not less, since a buyer could reasonably read it as clearance. Equally, the firm does not affirmatively claim its screening substitutes for counsel, so this is an omission rather than the misrepresentation the rubric scores 1-2.

What this dimension measures: What the firm does before candidates reach the client: knockout searches, class strategy, and how it hands off to trademark counsel. A stated pre-screening step with honest boundaries — screening is not legal clearance, and firms that say so score better than firms that imply it is — scores 4-5. Silence on trademark process scores 2, because presenting unscreened names wastes the one thing this purchase buys. Any implication that the firm's screening substitutes for counsel is a red flag, scored 1-2. Counts for 15% of the weighted score.

Evidence: vendor stated — the agency’s own claim, recorded as theirs rather than ours.

Scope and pricing transparencyWeak

No fee, range, starting point or engagement-size figure appears anywhere on the firm's own site across the eight pages read; the Rx and device pages route all commercial questions to contact@brandinstitute.com or +1 305-374-2500. The only pricing signal located is third-party: the Clutch profile, read first-hand, lists a minimum project size of $5,000+ and indicates most reviewed projects fell in the $50,000-$199,999 band. A directory minimum is not the firm publishing a fee. Partly offset by genuine scope honesty - the six service lines (strategy, name development, trademark searches, market research, regulatory, visual identity) are presented as separately commissioned, so a buyer can see that naming, trademark work and visual identity are distinct purchases rather than one implied full rebrand. That separation is why this lands at Weak rather than Poor.

What this dimension measures: Naming fees are famously opaque. Published fees, ranges or stated starting points score 4-5. A stated engagement structure without numbers scores 2-3. Nothing at all scores 1-2. Score scope honesty alongside: a firm that states what a naming engagement excludes (identity, strategy, legal filing) is more useful than one implying a full rebrand. Counts for 15% of the weighted score.

Evidence: partly checkable — corroborated in part against the sources below; the remainder rests on the agency’s own account.

Stronger here: Tanj scores Strong on the same dimension.

Deliverables and rounds clarityAdequate

Deliverables are defined in kind but not in quantity: original name candidates, trademark screening results, linguistic evaluation reports, name safety testing via the Drug Safety Institute, and recommendations tiered by regulatory viability. A contingency for clearance failure is stated, which is rare in this category - the Rx name development page commits that 'We guarantee a partnership until your compound name is approved. Period.' Kept at Adequate rather than the top band because the shortlist size is never stated: no page gives candidates per round or the number of rounds, so a buyer cannot know the size of the visible output before contracting. The approval guarantee is also unquantified - it does not say whether continued work carries additional fees, which is the part that determines what the commitment is actually worth.

What this dimension measures: What the client actually receives: how many candidate names per round, how many rounds, what accompanies them (rationale, screening results, territory map), and what happens if every candidate dies in legal. A stated structure with a stated contingency for clearance failure scores 4-5. Undefined deliverables score 2 — in a category where the visible output is a shortlist, not knowing its size before contracting is buying blind. Counts for 10% of the weighted score.

Evidence: vendor stated — the agency’s own claim, recorded as theirs rather than ours.

Turnaround and schedulingWeak

No engagement timeline is published on any page read - no kickoff-to-candidates duration, no stage lengths, no indication of how long regulatory name safety review adds to a project, which is the schedule question that matters most for a pharma naming buy given the multi-year approval cycle. The only scheduling evidence is second-hand and unquantified: Clutch reviewers describe 'well defined timelines' and note the firm handled 'complex and time-sensitive projects,' and all three rate schedule 5.0. That speaks to reliability against a schedule, not to a schedule a prospective buyer can see before contracting. Undisclosed scheduling scores at the rubric's stated floor.

What this dimension measures: Stated engagement timelines from kickoff to final candidates. Published, realistic timelines score 4-5 — naming projects run weeks, not days, and honesty beats speed. Undisclosed scheduling scores 2. Counts for 10% of the weighted score.

Evidence: inferred — our reading of indirect evidence, not a documented fact.

Stronger here: River + Wolf scores Excellent on the same dimension.

References and review baseAdequate

The Clutch profile was read first-hand: 5.0 out of 5 overall from 3 verified reviews, with cost rated 4.8. Reviewers cite the balance between creativity and regulatory knowledge, access to ex-FDA reviewers, well-organized projects, and expertise on complex time-sensitive work; no reviewer identified an area for improvement. Three reviews is a handful, not a substantial base, which is the rubric's 2-3 band - and the rubric weights this at 0.05 precisely because a thin review footprint is normal for a firm running a small number of large annual engagements. Supplemented by dated press releases naming client companies, which function as checkable references of a different kind. Note that the claim of a Clutch #1 naming-agency ranking surfaced in search snippets and was not confirmed on the Clutch profile itself, so it is not counted here.

What this dimension measures: Independent, verified reviews or checkable client references. A substantial verified base scores 4-5; a handful scores 2-3; none scores 2. Low weight deliberately: boutique naming firms run on referral and small annual project counts, so a thin review footprint is normal and the in-market names matter more. Counts for 5% of the weighted score.

Evidence: verified — checked against a named source you can open; the links under Sources below are where to check it yourself.

Verdict

Brand Institute is a genuine naming consultancy and a clear fit for this category: naming is not one line among many but the whole business, running from brand name and nonproprietary (USAN/INN) name development through trademark prescreening, market research, regulatory name safety and visual identity. Founded in 1993 in New York and headquartered in Miami since 1996, it lists roughly 18 offices across the US, Europe, Asia and South America.

Its distinguishing asset is regulatory: the wholly-owned Drug Safety Institute, established 2004, is staffed by former naming officials from the FDA, EMA, Health Canada, the AMA and WHO, and the firm publishes 2025 approval rates by jurisdiction (FDA 88 percent, EMA 76 percent, Health Canada 97 percent, Japan 76 percent, USAN 76 percent, INN 79 percent). For a buyer naming a drug, that is a materially different purchase from a general naming boutique - the constraint is not whether the name is good but whether a regulator will let it exist, and this firm is organised around that constraint.

The method disclosure is more specific than most firms in this category manage. Screening runs across a stated 268 international trademark databases via BrandReality, a pharma-in-use legal prescreen, plus a common-law prescreen; candidates are checked against the FDA POCA system with a stated pass condition of not exceeding a 75 percent combined phonetic and orthographic score; and linguistic evaluation is done by in-country native speakers in the client's primary markets rather than by database lookup. Names are then tiered by regulatory viability.

Those are named mechanisms with stated thresholds, not the generic 'we brainstorm then check' the rubric penalises. The in-market evidence is correspondingly strong and current: a long roster of real shipped brands, client-joint press releases carrying FDA approval dates, and an archive running to April 2026.

What a buyer cannot see is the commercial shape of the engagement, and the gap is wide. Across eight pages of the firm's own site there is no fee, no range, no starting point, no project duration, and no statement of how many candidate names arrive or in how many rounds. Everything commercial routes to a phone number and an email address.

The only pricing datum located anywhere is the Clutch profile's $5,000+ minimum and a $50,000-$199,999 typical band - useful, but a directory's figure, not the firm's disclosure. There is one notable exception to the opacity: the Rx page states a contingency for clearance failure, guaranteeing partnership until the compound name is approved, which is more than most naming firms will commit to in writing. It is also unpriced, so what it costs to invoke is unknown.

Two limits should be read alongside the strengths. First, the specific name credits rest largely on the firm's own press releases; the Wikipedia entry on the company carries an explicit warning that it may rely excessively on sources too closely associated with the subject, and a FiercePharma article on the Comirnaty naming returned 403 and could not be read first-hand, so independent third-party attribution of individual names was not established here. Second, the firm employs attorneys and paralegals in-house for trademark searches but nowhere states the boundary between a prescreen and legal clearance, nor describes a handoff to the client's own trademark counsel.

Firms that state that boundary plainly are more useful than firms that leave it ambiguous, and the ambiguity matters more, not less, when the searches are run by lawyers. The regulatory depth here is real and checkable in kind; the terms of the purchase are not published at all.

What you can do next

Koolav can make the introduction and handle the back-and-forth, or you can go straight to the agency.

Visit their website

This agency has not published a paid trial. What a paid trial is.

What we verified

Each claim below was checked against a named source, last on 2026-08-26. Follow any of them and check for yourself — that is the point of publishing them.

What other platforms say

Clutch {'score': 5.0, 'count': 3}

Read first-hand on the Clutch profile: 5.0 out of 5 across 3 verified reviews, cost rated 4.8, minimum project size $5,000+. Reviewers consistently cite the combination of creative and regulatory knowledge, access to former FDA reviewers, well-defined timelines and responsiveness on complex, time-sensitive healthcare naming projects; none listed an area for improvement. Three reviews is a thin base in absolute terms, though normal for a firm running a small number of large annual engagements. No readable G2 or Google review base was located. A claimed Clutch #1 naming-agency ranking appeared only in search snippets and was not confirmed on the Clutch profile itself, so it is not treated as evidence.

These are other platforms' numbers, not ours. We report them because they are part of the picture, and we do not average them into our score — our score comes from the published rubric above.

Red flags

What we could not verify

Sources

Others we evaluated in Brand Naming

Same rubric, same evaluator, same date range — so these are directly comparable to the verdict above.

See all 18 Brand Naming agencies we evaluated →

Think this is wrong?

If anything on this page is wrong or out of date, send us the correction and we will re-read the site.

Evidence moves a verdict. Money never does — no agency pays us for a listing, a placement, or a re-review. Whatever we conclude we publish, including that the verdict stands.